GOECP/SEOR radiotheraphy guidelines for non-small-cell lung cancer

doi:10.5306/wjco.v13.i4.237

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10068)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-10) series.

Item

Count

PDF

1038

WORD

HTML

6894

Tables (1-10)

386

Sum=8388

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

221

Download

474

Sum=695

Publishing Process of This Article

Item

Count

Browse

347

Download

638

Sum=985

Apr 24, 2022 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Guidelines

World J Clin Oncol. Apr 24, 2022; 13(4): 237-266
Published online Apr 24, 2022. doi: 10.5306/wjco.v13.i4.237

Table 5 Radiation therapy in patients with oligometastatic non-small cell lung cancer

Ref.	Type	Design	Palliative treatment	Histology	Presentation	No. of metastases/location	RT type	Follow-up (mo)	PFS (mo)	MFS (mo)	OS (mo)
Gomez et al[93], 2019	Phase II RCT. Multicentre	Induct. ChT: (RT + MT) vs MT	49	NSCLC (No EGFR, ALK)	Synchronous. Metachronous	≤ 3 (1%:65%)/lung, CNS, bone, liver SSRR, nodes	SABR/SBRT (MTX) hypofra. RT (primary)	38.8	14.2 (SABR/SBRT + MT) vs 4.4 (MT)	11.9 (SABR/SBRT + MT) vs 5.7	41 (SABR/SBRT + MT) vs 17
Iyengar et al[95], 2018	Phase II RCT. Multicentre	Induct. ChT: (SBRT + mChT) vs mChT	29	NSCLC (No GFR, ALK)	Synchronous	≤ 5 (1%:21%, 2%-3%:76%)/lung, lymph, bone, SSRR	SABR/SBRT (MTX) hypofra. RT (primary)	9.6¹	9.7 (SABR/SBRT + MT) vs 3.5 (MT)	NR	NR (SABR/SBRT + MT) vs 17
Palma et al[94], 2020	Phase II RCT. Multicentre	(ChT + PT) vs (ChT + SABR/SBRT)	99	Lung (18/99)	Synchronous. Metachronous	≤ 5 (1%-3%:93%)/lung, bone, CNS, liver, SSRR	SABR/SBRT	51	11.6 (SABR/SBRT + MT) vs 5.4 (TP-MT)	NR	50 (SABR/SBRT + MT) vs 22

¹Study stopped early due to significant difference in progression-free survival between the two arms.

RT: Radiotherapy; MT: Maintenance treatment; mChT: Maintenance chemotherapy; SABR: Stereotactic ablative radiotherapy; SBRT: Stereotactic body radiotherapy; EGFR: Epidermal growth factor receptor; ALK: Anaplastic lymphoma kinase; MTX: Metastasis; NR: Not reported; PFS: Progression-free survival; MFS: Metastasis-free survival; OS: Overall survival; PT: Palliative treatment; NSCLC: Non-small cell lung cancer.

Citation: Rodríguez De Dios N, Navarro-Martin A, Cigarral C, Chicas-Sett R, García R, Garcia V, Gonzalez JA, Gonzalo S, Murcia-Mejía M, Robaina R, Sotoca A, Vallejo C, Valtueña G, Couñago F. GOECP/SEOR radiotheraphy guidelines for non-small-cell lung cancer. World J Clin Oncol 2022; 13(4): 237-266
URL: https://www.wjgnet.com/2218-4333/full/v13/i4/237.htm
DOI: https://dx.doi.org/10.5306/wjco.v13.i4.237